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CytotoxicityAbstract Designed as potential cytotoxic agents a series of 6-substituted 2,3-dihydro-1H-
pyrrolo[3,2,1-ij]quinoline derivatives were synthesized by using a Bischler type reaction. The
methodology involved the cyclodehydration of 2-(3,4-dihydroquinolin-1(2H)-yl)-1-alkyl/aryl
ethanones in the presence of p-TSA under ultrasound irradiation. A number of compounds were
prepared using this methodology and tested for their in vitro anti-proliferative properties against
cancer (leukemia) and non-cancerous cell lines. Some of the compounds showed promising and
selective cytotoxic effects toward leukemia cells.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The pyrrolo[3,2,1-ij]quinoline framework has been found to be
an integral part of several bioactive molecules and agents
(Stanton and Ackerman, 1983; Al-awar et al., 2004). For
example, compounds containing this framework were foundto be useful for the potential treatment of asthma (Paris
et al., 1995), epilepsy, obesity (Isaac et al., 2000) and rice blast
diseases (Bass et al., 1981). This framework attracted our
attention because of a recent report that disclosed anti-
leukemic activity of a series of polycyclic isatin derivatives
including pyrrolo[3,2,1-ij]quinoline-1,2-diones (Matesic et al.,
2012). Indeed, the compound A (Fig. 1) that belongs to this
class showed notable cytotoxicity (IC50 = 8.36 ± 3.5 lM)
when tested against U937 cells. This report and our interest
(Layek et al., 2009a,b, 2011; Rao et al., 2014) in this class of
compounds prompted us to evaluate a library of compounds
based on 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinoline framework
B (Fig. 1). The substituent ‘‘R’’ was introduced at C-6 position
of the tricyclic ring not only for the creation of diversity butnd their
NO
O
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N
R
A B
Figure 1 The known pyrrolo[3,2,1-ij]quinoline-1,2-dione deriva-
tive A and the new framework B for the identiﬁcation of potential
cytotoxic agents.
2 M.S. Rao et al.also for the fact that 3-substituted indoles were found to be
antiproliferative agents (Rao et al., 2011).
While a number of methods have been reported for the con-
struction of pyrrolo[3,2,1-ij]quinoline or related rings all of
them involved in the use of expensive transition metals espe-
cially Pd/Cu catalysts (Layek et al., 2009a,b, 2011; Rao
et al., 2014; Marchand et al., 2005; Blurton et al., 1997;
Dorow et al., 2006). Moreover, all these methods are useful
for accessing compounds having a substituent at C-5 position
and not handy for the synthesis of compounds based on B. A
literature search revealed that the Bischler (Bischler and Brion,
1892; Bischler and Fireman, 1893) type of reaction (Shikhaliev
et al., 2003; Wijngaarden et al., 1993; Zhu et al., 2004; Adam-
Worrall, 2005) has been explored to prepare tricyclic com-
pounds possessing a substituent at C-6 similar to B. For exam-
ple, N-phenacyl derivatives of hydroquinolines were cyclized
to the corresponding pyrroloquinolines in the presence of an
acid catalyst (Shikhaliev et al., 2003). We therefore decided
to adopt a similar but faster strategy for accessing our target
compounds based on B. The ultrasound mediated reactions
have gained considerable interest in recent time. Compared
to the traditional methods the ultrasound mediated reactions
offer several advantages such as shorter reaction time, mild
conditions, and good yields of products (Li et al., 2005;
Ratoarinoro et al., 1992). Thus, the use of ultrasound radia-
tion has emerged as a common strategy in present day organic
synthesis. Herein we report an ultrasound mediated faster
approach toward 6-substituted 2,3-dihydro-1H-pyrrolo[3,2,1-
ij]quinoline derivatives (3) via a Bischler type reaction of
2-(3,4-dihydroquinolin-1(2H)-yl)-1-alkyl/aryl ethanone (2)
prepared from 1,2,3,4-tetrahydroquinoline (1) (Scheme 1). To
our knowledge the present strategy has not been explored for
the preparation of compound 3 earlier. We also report the
cytotoxicity of the synthesized compounds tested against
human chronic myeloid leukemia cells i.e. K562 in vitro.
Being a cancer of the blood-forming tissues, leukemiaN
H
RCOCH2Br
1,4-dioxane
K2CO3
70-75oC
3-4h
O
R1 2
Scheme 1 Ultrasound mediated synthesis of 6-substituted 2,3-dihyd
reaction.
Please cite this article in press as: Rao, M.S. et al., Ultrasound mediated synthesis
pharmacological evaluation. Arabian Journal of Chemistry (2015), http://dx.doi.orgis characterized by a large increase in the numbers of white
blood cells (leukocytes) in the circulation or bone marrow.
2. Material and methods
2.1. General methods
Unless stated otherwise, reactions were monitored by thin
layer chromatography (TLC) on silica gel plates (60 F254),
visualizing with ultraviolet light or iodine spray. Column chro-
matography was performed on silica gel (60–120 mesh) using
distilled petroleum ether and ethyl acetate. 1H and 13C NMR
spectra were determined in CDCl3 solution using a Varian
400 MHz spectrometer. Proton chemical shifts (d) are relative
to tetramethylsilane (TMS, d= 0.0) as internal standard and
expressed in parts per million. Spin multiplicities are given as
s (singlet), d (doublet), t (triplet), and m (multiplet) as well
as b (broad). Coupling constants (J) are given in hertz.
Infrared spectra were recorded on a FTIR spectrometer.
Melting points were determined by using a Buchi melting point
B-540 apparatus. MS spectra were obtained on a mass
spectrometer.
2.2. Preparation of compound 2
To a solution of compound 1 (1 mmol) and a-bromo ketone
(0.95 mmol) in 1,4-dioxane (5 mL) was added K2CO3 (1 mmol)
and the mixture was stirred at 70–75 C for 3–4 h under nitro-
gen. After completion of the reaction (indicated by TLC) the
mixture was concentrated under reduced pressure and diluted
with cold water (25 mL). The mixture was extracted with
EtOAc (3 · 5 mL). The combined organic layer was collected,
washed with water (2 · 5 mL), dried over anhydrous Na2SO4,
ﬁltered and concentrated under low vacuum. The product
obtained was used for the next step.
2.3. General procedure for the preparation of compound 3
A solution of compound 2 (1 mmol) and p-TSA (0.5 mmol) in
1,4-dioxane (3 mL) was heated at 80 C in the presence of
nitrogen under ultrasound (using a laboratory ultrasonic bath
SONOREX SUPER RK 510H model producing irradiation of
35 kHz) for 2 h. The reaction mixture was then concentrated
under vacuum, diluted with EtOAc (10 mL), and washed with
1 N K2CO3 solution (2 · 5 mL) followed by cold water. The
EtOAc layer was collected, dried over anhydrous Na2SO4, ﬁl-
tered and concentrated under low vacuum. The crude product
isolated was puriﬁed by column chromatography over silica gel
using hexane–EtOAc as eluant.NN
R
p-TSA
1,4-dioxane
80oC
3
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Ultrasound mediated synthesis and pharmacological evaluation 32.4. 1-Phenyl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline (3a)
Light yellow solid; mp 61–63 C; 1H NMR (400 MHz, CDCl3)
d 7.75 (d, J = 7.9 Hz, 1H), 7.68–7.66 (m, 2H), 7.42–7.39 (m,
2H), 7.26–7.21 (m, 2H), 7.10–7.07 (m, 1H), 6.95 (d,
J = 7.0 Hz, 1H), 4.17 (t, J = 6.0 Hz, 2H), 3.02 (t,
J = 6.0 Hz, 2H), 2.27–2.22 (m, 2H); 13C NMR (100 MHz,
CDCl3) d 136.1, 135.0, 128.7, 126.8, 125.4, 123.7, 123.6,
122.0, 120.3, 119.0, 117.5, 116.5, 44.1, 24.7, 22.6; MS (ESI)
m/z: 233 (100), 232 (33), 204 (6), 154 (5), 88 (2); HRMS
(ESI) for C17H16N (M+H)+: calcd 234.1277, found 234.1285.
2.5. 1-(4-Fluorophenyl)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline
(3b)
Oily liquid; 1H NMR (400 MHz, CDCl3) d 7.67 (d,
J = 8.0 Hz, 1H), 7.59 (d, J = 8.3 Hz, 2H), 7.20 (s, 1H),
7.14–7.04 (m, 3H), 6.95 (d, J = 7.0 Hz, 1H), 4.18 (t,
J = 6.0 Hz, 2H), 3.02 (t, J = 6.0 Hz, 2H), 2.30–2.19 (m,
2H); 13C NMR (100 MHz, CDCl3) d 161.1 (d, J C –
F = 242.5 Hz), 134.8, 132.1 (d, J C – F = 3.1 Hz), 128.1 (d,
J C – F = 7.6 Hz), 123.6, 123.4, 122.0, 120.4, 119.0, 117.1,
115.6, 115.5 (d, J C – F = 21.1 Hz), 44.1, 24.6, 22.7; MS
(ESI) m/z: 251 (100), 232 (9), 207 (5), 154 (11), 125 (11) 75
(4); HRMS (ESI) for C17H15FN (M+H)+: calcd 252.1183,
found 252.1180.
2.6. 1-(4-Chlorophenyl)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline
(3c)
Light brown solid; mp 125–127 C;1H NMR (400 MHz,
CDCl3) d 7.68 (d, J = 8.0 Hz, 1H), 7.59–7.56 (m, 2H), 7.37–
7.34 (m, 2H), 7.23 (s, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.95 (d,
J = 7.0 Hz, 1H), 4.16 (t, J = 6.0 Hz, 2H), 3.00 (t,
J = 6.0 Hz, 2H), 2.26–2.21 (m, 2H); 13C NMR (100 MHz,
CDCl3) d 135.0, 134.6, 131.0, 128.8, 128.0, 123.7, 123.5,
122.1, 120.5, 119.1, 117.2, 115.3, 44.2, 24.6, 22.7; MS (ESI)
m/z: 267 (100), 266 (36), 230 (15), 154 (11), 88 (25) 75 (10);
HRMS (ESI) for C17H15ClN (M+H)+: calcd 268.0888,
found 268.0884.
2.7. 1-(4-Bromophenyl)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline
(3d)
Pale yellow solid; mp 153–155 C;1H NMR (400 MHz, CDCl3)
d 7.71–7.68 (m, 1H), 7.56–7.52 (m, 4H), 7.27 (s, 1H), 7.12 (d,
J = 7.9 Hz, 1H), 6.98 (d, J = 7.0 Hz, 1H), 4.20 (t,
J = 6.0 Hz, 2H), 3.02 (t, J = 6.0 Hz, 2H), 2.30–2.26 (m,
2H); 13C NMR (100 MHz, CDCl3) d 135.1, 135.0, 131.7,
128.2, 123.8, 123.4, 122.1, 120.6, 119.1, 118.8, 117.2, 115.3,
44.2, 24.6, 22.7; MS (ESI) m/z: 311 (100), 313 (98), 312 (40),
230 (20), 102 (15); HRMS (ESI) for C17H15BrN (M+H)+:
calcd 312.0382, found 312.0376.
2.8. 1-(p-Tolyl)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline (3e)
Ash colored solid; mp 101–103 C;1H NMR (400 MHz,
CDCl3) d 7.73 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 7.4 Hz, 2H),
7.24–7.22 (m, 3H), 7.07 (t, J = 7.4 Hz, 1H), 6.94
(d, J = 7.0 Hz, 1H), 4.18 (t, J = 6.0 Hz, 2H), 3.01Please cite this article in press as: Rao, M.S. et al., Ultrasound mediated synthesis
pharmacological evaluation. Arabian Journal of Chemistry (2015), http://dx.doi.org(t, J = 6.0 Hz, 2H), 2.38 (s, 3H), 2.28–2.24 (m, 2H); 13C
NMR (100 MHz, CDCl3) d 134.0, 133.8, 132.1, 128.5, 125.7,
122.6, 122.3, 120.8, 119.1, 117.7, 116.4, 115.5, 43.0, 23.6,
21.7, 20.0; MS (ESI) m/z: 247 (100), 246 (35), 231 (8), 154
(10), 128 (16) 73 (4); HRMS (ESI) for C18H18N (M+H)+:
calcd 248.1434, found 248.1431.
2.9. 1-(4-Methoxyphenyl)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline
(3f)
Pale yellow solid; mp 124–126 C;1H NMR (400 MHz, CDCl3)
d 7.71 (d, J = 8.1 Hz, 1H), 7.62–7.60 (m, 2H), 7.20 (s, 1H),
7.07 (d, J = 8.0 Hz, 1H), 7.01–6.95 (m, 3H), 4.18 (t,
J = 6.0 Hz, 2H), 3.86 (s, 3H), 3.00 (t, J = 6.0 Hz, 2H), 2.29–
2.25 (m, 2H); 13C NMR (100 MHz, CDCl3) d 157.7, 134.8,
128.7, 128.1, 123.7, 123.2, 122.0, 120.1, 118.9, 117.6, 116.4,
114.3, 55.3, 44.3, 24.9, 22.9; MS (ESI) m/z: 263 (100), 248
(92), 240 (11), 192 (60), 131 (12); HRMS (ESI) for
C18H18NO (M+H)+: calcd 264.1383, found 264.1380.
2.10. 4-(5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)benzonitrile
(3g)
Ash colored solid; mp 133–135 C;1H NMR (400 MHz,
CDCl3) d 7.75–7.71 (m, 3H), 7.66–7.64 (m, 2H), 7.37 (s, 1H),
7.14 (d, J = 7.9 Hz, 1H), 7.01 (d, J = 7.0 Hz, 1H), 4.20 (t,
J = 6.0 Hz, 2H), 3.01 (t, J = 6.0 Hz, 2H), 2.29–2.24 (m,
2H); 13C NMR (100 MHz, CDCl3) d 141.1, 135.2, 132.5,
126.4, 125.0, 123.3, 122.4, 121.2, 119.5, 119.6, 117.2, 114.7,
108.1, 44.4, 24.6, 22.5; MS (ESI) m/z: 258 (100), 242 (5), 230
(6), 202 (4), 128 (8); HRMS (ESI) for C18H15N2 (M+H)+:
calcd 259.1230, found 259.1226.
2.11. 1-(Naphthalen-2-yl)-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline
(3h)
Light brown solid; mp 113–115 C;1H NMR (400 MHz,
CDCl3) d 8.12 (s, 1H), 7.89–7.85 (m, 3H), 7.83–7.80 (m, 2H),
7.49–7.45 (m, 1H), 7.43–7.39 (m, 2H), 7.14 (d, J = 7.8 Hz,
1H), 7.01 (d, J = 7.0 Hz, 1H), 4.21 (t, J = 6.0 Hz, 2H), 3.03
(t, J = 6.0 Hz, 2H), 2.32–2.25 (m, 2H); 13C NMR (100 MHz,
CDCl3) d 135.0, 134.1, 133.5, 131.7, 128.1, 127.6, 127.7,
126.0, 126.1, 125.0, 124.2, 124.1, 123.8, 122.1, 120.5, 119.1,
117.6, 116.4, 44.2, 24.7, 22.6; MS (ESI) m/z: 283 (100), 254
(7), 226 (5), 141 (8), 139 (4); HRMS (ESI) for C21H18N
(M+H)+: calcd 284.1434, found 284.1428.2.12. 1-(3a,7a-Dihydrobenzofuran-2-yl)-5,6-dihydro-4H-pyrrolo
[3,2,1-ij]quinoline (3i)
Ash colored solid; mp 136–138 C; 1H NMR (400 MHz,
CDCl3) d 7.79 (d, J = 7.9 Hz, 1H), 7.60 (s, 1H), 7.54–7.53
(m, 1H), 7.47–7.46 (m, 1H), 7.20–7.15 (m, 3H), 7.00 (d,
J = 7.0 Hz, 1H), 6.85 (d, J = 0.4 Hz, 1H), 4.19 (t,
J = 6.0 Hz, 2H), 3.01 (t, J = 6.0 Hz, 2H), 2.28–2.23 (m,
2H); 13C NMR (100 MHz, CDCl3) d 153.8, 153.4, 134.7,
130.1, 124.6, 122.8, 122.7, 122.5, 122.2, 121.0, 120.0, 119.5,
117.7, 110.4, 107.1, 98.7, 44.4, 24.5, 22.7; MS (ESI) m/z: 273
(100), 245 (6), 189 (3), 136 (6), 120 (3); HRMS (ESI) for
C19H18NO (M+H)+: calcd 274.1226, found 274.1221.of 6-substituted 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinoline derivatives and their
/10.1016/j.arabjc.2015.05.013
Table 1 The effect of reaction conditions on the conversion of
2a to 3a.a
NN
O
Ph
Ph
solvent
2a 3a
catalyst
Entry Catalyst Solvent Time (h) % Yieldb
1 AcOH MeCN 28 0
2 CF3CO2H MeCN 28 Trace
3 p-TSA MeCN 28 21
4 p-TSA Toluene 28 27
5 p-TSA 1,4-Dioxane 28 53
6 p-TSA 1,4-Dioxane 2 67c
7 p-TSA 1,4-Dioxane 2 49c,d
a All the reactions were performed using 2a (1 mmol) and catalyst
(0.5 mmol) in a solvent (3 mL) at 80 C under nitrogen.
b Isolated yield.
c The reaction was performed in the presence of ultrasound.
d The reaction was performed at 50 C instead of 80 C.
4 M.S. Rao et al.2.13. Ethyl 2-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)
acetate (3j)
Yellow oil; 1H NMR (400 MHz, CDCl3) d 7.40 (d, J = 8.0 Hz,
1H), 7.03–7.00 (m, 2H), 6.89 (d, J = 7.0 Hz, 1H), 4.14 (q,
J = 7.0 Hz, 2H), 4.09 (t, J = 6.0 Hz, 2H), 3.73 (s, 2H), 2.94
(t, J = 6.0 Hz, 2H), 2.22–2.17 (m, 2H), 1.26–1.23 (m, 3H);
13C NMR (100 MHz, CDCl3) d 172.1, 134.2, 125.1, 125.0,
121.5, 119.4, 118.4, 116.5, 106.7, 60.4, 44.0, 31.5, 24.4, 22.6,
14.1; MS (ESI) m/z: 170 (100), 142 (27), 243 (3), 83 (2);
HRMS (ESI) for C15H18NO2 (M+H)+: calcd 244.1332,
found 244.1329.
2.14. 1-Ethyl-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline (3k)
Yellow liquid; 1H NMR (400 MHz, CDCl3) d 7.39 (d,
J = 7.7 Hz, 1H), 7.00–6.95 (m, 1H), 6.87 (d, J = 7.0 Hz,
1H), 6.83 (s, 1H), 4.11–4.04 (m, 2H), 2.97 (t, J = 5.9 Hz,
2H), 2.78–2.74 (m, 2H), 2.22–2.19 (m, 2H), 1.32–1.29 (m,
3H); 13C NMR (100 MHz, CDCl3) d 134.4, 125.0, 122.5,
121.4, 118.7, 118.1, 117.2, 116.4, 43.6, 24.5, 23.0, 18.5, 15.0;
MS (ESI) m/z: 185 (37), 170 (100), 168 (4), 142 (16), 115 (5);
HRMS (ESI) for C13H16N (M+H)+: calcd 186.1277, found
186.1273.
2.15. MTT assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. Cells (5 · 103
cells/well) were seeded to 96-well culture plate and cultured
with or without compounds at 10 lM concentration (ﬁve dif-
ferent concentrations i.e., 10, 5, 1, 0.5, and 0.1 lM for dose
response study) in duplicates for 24 h in a ﬁnal volume of
200 ll. After treatment, the medium was removed and 20 ll
of MTT (5 mg/ml in PBS) was added to the fresh medium.
After 3 h incubation at 37 C, 100 ll of DMSO was added to
each well and plates were agitated for 1 min. Absorbance
was read at 570 nm on a multi-well plate reader (Victor3,
Perkin Emler). Percent inhibition of proliferation was calcu-
lated as a fraction of control (without compound).
3. Results and discussion
3.1. Chemistry
The starting compound (2) required for the synthesis of 3 was
prepared (Bahner et al., 1952) via the reaction of 1 with
a-bromo ketones in the presence of K2CO3 in 1,4-dioxane at
70–75 C for 3–4 h. Initially, in certain cases the compound 2
was isolated and puriﬁed before use in the next step.
However, at a later stage we observed that the puriﬁcation
of compound 2 was not necessary and the crude product iso-
lated after usual work up could be used for the preparation
of the target compound 3. Nevertheless, to establish the opti-
mized reaction conditions we used the cyclization of 2-(3,4-
dihydroquinolin-1(2H)-yl)-1-phenylethanone (2a) as a model
reaction (Table 1). The reaction was performed in MeCN
using various acid catalysts e.g. AcOH, CF3CO2H and p-
TSA (p-toluenesulfonic acid) (entries 1–3, Table 3) when the
desired product 3a was isolated in low yield only in third casePlease cite this article in press as: Rao, M.S. et al., Ultrasound mediated synthesis
pharmacological evaluation. Arabian Journal of Chemistry (2015), http://dx.doi.org(entry 3, Table 1). The change of solvent to toluene did not
improve the product yield signiﬁcantly (entry 4, Table 1).
However, 3a was isolated in 53% yield when the reaction
was performed in 1,4-dioxane (entry 5, Table 1). The duration
of all these reactions was 24 h. To decrease the reaction time
we performed the reaction under ultrasound irradiation using
a laboratory ultrasonic bath SONOREX SUPER RK 510H
model producing irradiation of 35 kHz. To our delight the
reaction was completed within 2 h affording 3a in 67% yield
(entry 6, Table 1). All these reactions in the absence or pres-
ence of ultrasound were generally performed at 80 C. The
lowering of reaction temperature decreased the yield of 3a con-
siderably (entry 7, Table 1). Thus, the condition of entry 6 was
found to be optimum and used for further study.
To extend the scope and generality of this methodology, a
number of ethanone derivatives (2) were treated with p-TSA in
1,4-dioxane under the conditions of entry 6 of Table 1. Both
aromatic and aliphatic substituents as ‘‘R’’ group were exam-
ined (Table 2). The reaction proceeded well in all these cases
affording the corresponding 6-substituted 2,3-dihydro-1H-
pyrrolo[3,2,1-ij]quinoline derivatives (3) in good to acceptable
yields (Table 2). Aromatic ‘‘R’’ moiety containing various type
of substituents such as mild or strong electron-donating
groups such as F, Cl, Br, Me, OMe (entries 1–6, Table 2)
and electron-withdrawing such as CN (entry 7, Table 2) was
examined and well tolerated except the case of CN. The pres-
ence of aromatic groups such as 2-naphthyl or benzofuran-2-yl
was also tolerated (entries 8 and 9, Table 2). The aliphatic ‘‘R’’
moiety such as –CH2CO2Et and ethyl (entrys 10 and 11,
Table 2) was generally found to be tolerated under the condi-
tion employed though the product yield was not particularly
high in the ﬁrst case possibly due to the cleavage of ester group
leading to the corresponding acid thereby partial loss of the
product 3j.
A plausible mechanism (Shikhaliev et al., 2003) for the
ultrasound mediated synthesis of 6-substituted 2,3-dihydro-of 6-substituted 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinoline derivatives and their
/10.1016/j.arabjc.2015.05.013
Table 2 Synthesis of 6-substituted 2,3-dihydro-1H-pyrrolo
[3,2,1-ij]quinoline derivatives (3).a
NN
O
R
R
p -TSA
1,4-dioxane
80oC
2 3
.
Entry Substrateb 2; R = Product 3 % Yieldc
1 Ph 3a 67
2 C6H4F-p 3b 78
3 C6H4Cl-p 3c 76
4 C6H4Br-p 3d 73
5 C6H4Me-p 3e 83
6 C6H4OMe-p 3f 78
7 C6H4CN-p 3g 51
8 2-Naphthyl 3h 69
9 Benzofuran-2-yl 3i 70
10 CH2CO2Et 3j 60
11 Et 3k 82
a Reactions were performed using 2 (1 mmol) and p-TSA
(0.5 mmol) in 1,4-dioxane (3 mL) at 80 C under ultrasound for 2 h
under nitrogen.
b The compound 2 prepared for this step was used without
purifying further.
c Isolated yield.
Table 3 In vitro antiproliferative properties of compound 3@
10 lM against cancer and non-cancerous cells.
N
R
3
.
Entry Compound 3; R = % Inhibition of proliferationa
K562 Leukemia HEK293b
Non-cancerous
1 3a; Ph 38.0 0.3
2 3b; C6H4F-p 50.9 0.5
3 3c; C6H4Cl-p 35.6 1.6
4 3d; C6H4Br-p 33.8 1.2
5 3e; C6H4Me-p 51.2 0.7
6 3f; C6H4OMe-p 65.7 2.8
7 3g; C6H4CN-p 33.8 2.1
8 3h; 2-Naphthyl 23.0 3.9
9 3i; Benzofuran-2-yl 24.8 2.4
10 3j; CH2CO2Et 35.1 1.6
11 3k; Et 21.1 0.8
aData represent the mean values of three independent
determinations.
b HEK293 cell line was used as noncancerous cell line.
p-TSA
N
OH
R
N
OH
R
H
N
OH2
R
H
3 2
-H2O
E-1
E-2
E-3
Scheme 2 Proposed reaction mechanism for the cyclodehydra-
tion of 2 leading to 3.
Ultrasound mediated synthesis and pharmacological evaluation 51H-pyrrolo[3,2,1-ij]quinoline derivatives (3) in the presence of
p-TSA is shown in Scheme 2. The cyclodehydration process
seemed to proceed via generation of the protonated speciesPlease cite this article in press as: Rao, M.S. et al., Ultrasound mediated synthesis
pharmacological evaluation. Arabian Journal of Chemistry (2015), http://dx.doi.orgE-1 (from compound 2) which on intramolecular cyclization
afforded E-2. This intramolecular attack by the benzene ring
was facilitated by the ring nitrogen of E-1. Re-aromatization
of the benzene ring of E-2 followed by protonation of the
hydroxyl group afforded E-3. The elimination of water mole-
cule from E-3 and regeneration of proton completed the cat-
alytic cycle affording the desired product 3. It is worthy to
note that electron donating or withdrawing effect of ‘‘R’’
group attached to the carbonyl moiety could inﬂuence the elec-
tropositivity of carbonyl carbon thereby intramolecular
cyclization of E-1. Thus the p-cyanophenyl group due to its
electron withdrawing effect did not allow adequate degree of
polarization of AC‚OH+ bond to facilitate the intramolecu-
lar attack by the nucleophilic phenyl moiety at the carbonyl
carbon.
The results of Table 1 (entry 5 vs. 6) clearly suggest that the
synthesis of compound 3 was accelerated in the presence of
ultrasound though it is not clear if the ultrasound irradiation
has effect on one or more of steps shown in Scheme 2. It is pos-
sible that the force created due to the cavitational collapse can
drive all the steps. Being a well known phenomenon cavitation
caused by ultrasound is involved with the growth, oscillation,
and collapse of bubbles under the action of an acoustic ﬁeld
(Mason and Peters, 1991; Mason, 2007). The cavitational col-
lapse on the other hand creates drastic conditions inside the
medium within an extremely short period of time. For exam-
ple, the temperature of 2000–5000 K and pressure up to 1800
atmosphere can be produced inside the collapsing cavity under
sonic conditions. Also, strong physical effects including shear
forces, jets, and shock waves are caused by this collapse out-
side the bubble. Thus, chemical transformations performed
under ultrasound proceed with notable efﬁciency and speed
due to these cavitation-induced overall effects. This perhaps
explains the rate acceleration of the present reaction under
ultrasound in the absence of which the reaction took relatively
longer time (entry 5, Table 1).of 6-substituted 2,3-dihydro-1H-pyrrolo[3,2,1-ij]quinoline derivatives and their
/10.1016/j.arabjc.2015.05.013
Table 4 In vitro antiproliferative effects of compound 3f
against K562 Leukemia cells.
Compounds % Inhibition of proliferationa
10 lM 5 lM 1 lM 0.1 lM 0.01 lM
3f 66 51 37 23 ND
Doxorubicin 82 70 59 47 32
ND= not determined.
aAverage of three determinations.
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All the compounds of 3 synthesized based on the template B
(Fig. 1) were evaluated for their potential anticancer properties
in vitro. The cells used for our in vitro studies include human
chronic myeloid leukemia cells such as K562, and non-
cancerous human embryonic kidney cells such as HEK293.
The effect of test compounds on cell viability was measured
using a colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-di
phenyltetrazolium bromide] assay after 24 h of treatment in
culture medium containing PBS. The percentages of cell viabil-
ity for most promising test compounds at 10 lM are presented
in Table 3. The compounds that showed >50% activities were
considered as active. As can be seen from Table 3 the com-
pounds 3b, 3e and 3f showed signiﬁcant activities against
K562 Leukemia cells whereas other compounds were found
to be less active or inactive. It is evident that the p-
substituent on the benzene ring of the ‘‘R’’ group played a
key role and F, Me as well as OMe were found to be favorable.
Notably, all these compounds were found to be selective
toward the growth inhibition of cancer cells as none of these
compounds showed any signiﬁcant effects when tested against
HEK293 cells. The best active compound 3f was taken further
for a dose response study (Table 4). The compound 3f showed
consistent dose-dependent growth inhibition of K562
Leukemia cells across all the concentrations tested. In view
of the fact that leukemia affected 352,000 people globally
and caused 265,000 deaths in 2012 (World Cancer Report,
2014), the compound 3f was identiﬁed as a new cytotoxic agent
and is of further interest.
4. Conclusion
In conclusion, a series of 6-substituted 2,3-dihydro-1H-
pyrrolo[3,2,1-ij]quinoline derivatives were designed and
synthesized as potential cytotoxic agents. Synthesis of these
compounds was carried out by using a Bischler type reaction
that involved the cyclodehydration of 2-(3,4-dihydroquinolin-
1(2H)-yl)-1-alkyl/aryl ethanones in the presence of p-TSA
under ultrasound irradiation. A number of compounds were
prepared using this methodology and tested for their in vitro
antiproliferative properties against cancer (leukemia) and
non-cancerous cell lines. Some of the compounds showed
promising and selective cytotoxic effects toward leukemia cells.
Overall, our study suggests that the 2,3-dihydro-1H-
pyrrolo[3,2,1-ij]quinoline framework could be an attractive
template for the identiﬁcation of novel and potential
anticancer agents and the corresponding synthetic strategyPlease cite this article in press as: Rao, M.S. et al., Ultrasound mediated synthesis
pharmacological evaluation. Arabian Journal of Chemistry (2015), http://dx.doi.orgdescribed could be useful for generating diversity based library
of small molecules related to this scaffold.Acknowledgments
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